<DOC>
	<DOCNO>NCT00283049</DOCNO>
	<brief_summary>The purpose study compare change hemoglobin A1c ( HbA1c ) baseline Week 12 3 treatment arm .</brief_summary>
	<brief_title>Insulin Glargine Injection Treatment Place Thiazolidinedione ( TZD ) , Sulfonylurea , Metformin Triple Agent Therapy Type 2 Diabetes Mellitus ( T2DM ) Adult Subjects With Unsatisfactory Control</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin glulisine</mesh_term>
	<mesh_term>2,4-thiazolidinedione</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<mesh_term>Insulin Glargine</mesh_term>
	<criteria>Subjects meet follow criterion consider enrollment study : 1 . 18 79 year age , inclusive 2 . Diagnosis type 2 diabetes mellitus 3 . Continuous treatment therapeutic dosage thiazolidinedione ( rosiglitazone pioglitazone ) , metformin , sulfonylurea daily prior enter study 4 . Screening HbA1c ≥ 7.0 % 5 . Fasting Cpeptide concentration ≥ 0.27 ng/ml 6 . Negative glutamic acid decarboxylase ( GAD ) antibodies 7 . Demonstrated ability willingness perform selfmonitoring blood glucose ( SMBG ) use plasmareferenced glucose meter maintain electronic diary 8 . Demonstrated ability willingness use electronic diary record SMBG result , insulin dos , hypoglycemic event . 9 . Signed , inform consent Health Insurance Portability Accountability Act ( HIPAA ) documentation 1 . Stroke , myocardial infarction , coronary artery bypass graft , percutaneous transluminal coronary angioplasty , angina pectoris , within last 12 month 2 . Cardiac status New York Heart Association ( NYHA ) IIIIV 3 . Impaired renal function show , limited , serum creatinine ≥ 1.5 mg/dL male , ≥ 1.4 mg/dL female 4 . Chronic use insulin : ( 3 week continuous use ) past 12 month 5 . Acute infection 6 . Clinically significant peripheral edema 7 . Acute chronic history metabolic acidosis , include diabetic ketoacidosis 8 . Clinical evidence active liver disease , serum alanine aminotransferase ( ALT ) aspartate aminotransferase ( AST ) 2.5 time upper limit normal range 9 . History hypoglycemia unawareness 10 . Pregnancy lactation 11 . Known hypersensitivity insulin glargine component Lantus® 12 . Known hypersensitivity insulin glulisine component Apidra® 13 . Any malignancy within last 5 year , exception adequately treat basal squamous cell carcinoma skin adequately treat cervical carcinoma situ 14 . Current addiction current alcohol abuse , history substance alcohol abuse within last 2 year 15 . Diagnosis dementia 16 . Subject investigator subinvestigator , research assistant , pharmacist , study coordinator , staff relative thereof directly involve conduct protocol 17 . Mental condition render subject unable understand nature , scope , possible consequence study . Subject unlikely comply protocol , e.g. , uncooperative attitude , inability return followup visit , unlikelihood complete study 18. subject currently take treat follow medication 3 month prior screen : Byetta ( exenatide ) , Starlix ( nateglinide ) , Prandin ( repaglinide ) , Januvia ( sitagliptin ) , Janumet ( metformin + sitagliptin ) 19 . Any disease condition opinion investigator and/or sponsor may interfere completion study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>79 Years</maximum_age>
	<verification_date>January 2011</verification_date>
</DOC>